TW202400228A - 減輕細胞激素釋放症候群的給藥方案 - Google Patents

減輕細胞激素釋放症候群的給藥方案 Download PDF

Info

Publication number
TW202400228A
TW202400228A TW112106608A TW112106608A TW202400228A TW 202400228 A TW202400228 A TW 202400228A TW 112106608 A TW112106608 A TW 112106608A TW 112106608 A TW112106608 A TW 112106608A TW 202400228 A TW202400228 A TW 202400228A
Authority
TW
Taiwan
Prior art keywords
dose
dosing regimen
administered
bispecific antibody
subject
Prior art date
Application number
TW112106608A
Other languages
English (en)
Chinese (zh)
Inventor
斯里肯斯 安巴蒂
阿菲亞 喬德里
赫舍姆 穆罕默德
馬舒德 哈卡莎托羅吉
朱敏
Original Assignee
美商再生元醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商再生元醫藥公司 filed Critical 美商再生元醫藥公司
Publication of TW202400228A publication Critical patent/TW202400228A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112106608A 2022-02-25 2023-02-23 減輕細胞激素釋放症候群的給藥方案 TW202400228A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202263313932P 2022-02-25 2022-02-25
US63/313,932 2022-02-25
US202263393212P 2022-07-28 2022-07-28
US63/393,212 2022-07-28
US202263420782P 2022-10-31 2022-10-31
US63/420,782 2022-10-31
US202263424210P 2022-11-10 2022-11-10
US63/424,210 2022-11-10
US202363440304P 2023-01-20 2023-01-20
US63/440,304 2023-01-20

Publications (1)

Publication Number Publication Date
TW202400228A true TW202400228A (zh) 2024-01-01

Family

ID=85778997

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112106608A TW202400228A (zh) 2022-02-25 2023-02-23 減輕細胞激素釋放症候群的給藥方案

Country Status (11)

Country Link
US (1) US20230272118A1 (https=)
EP (1) EP4482524A1 (https=)
JP (1) JP2025508832A (https=)
KR (1) KR20240167457A (https=)
CN (1) CN119156226A (https=)
AU (1) AU2023224098A1 (https=)
CA (1) CA3244791A1 (https=)
IL (1) IL315011A (https=)
MX (1) MX2024010292A (https=)
TW (1) TW202400228A (https=)
WO (1) WO2023164143A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CA3110513A1 (en) * 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
TW202135860A (zh) 2019-12-10 2021-10-01 美商再生元醫藥公司 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物

Also Published As

Publication number Publication date
AU2023224098A1 (en) 2024-09-12
IL315011A (en) 2024-10-01
MX2024010292A (es) 2024-12-06
US20230272118A1 (en) 2023-08-31
WO2023164143A1 (en) 2023-08-31
CN119156226A (zh) 2024-12-17
JP2025508832A (ja) 2025-04-10
EP4482524A1 (en) 2025-01-01
KR20240167457A (ko) 2024-11-26
CA3244791A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
US20230165959A1 (en) Dosing Strategy that Mitigates Cytokine Release Syndrome for Therapeutic Antibodies
JP6923292B2 (ja) 抗ｃｄ３抗体、ｃｄ３及びｃｄ２０に結合する二重特異性抗原結合分子、並びにそれらの使用
JP2019503363A (ja) 急性リンパ芽球性白血病を治療するための二重特異性の抗ｃｄ２０／抗ｃｄ３抗体
CN108137700A (zh) 抗psma抗体、结合psma及cd3的双特异性抗原结合分子及其用途
US20230272118A1 (en) Dosing Regimens for Mitigation of Cytokine Release Syndrome
KR20250156813A (ko) 이중특이성 항-CD22 x 항-CD28 분자를 이용한 암 치료 방법
RU2799529C2 (ru) Стратегия дозирования, уменьшающая синдром высвобождения цитокинов для биспецифичных антител к cd3/c20
HK40121299A (en) Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
HK40056070B (en) Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
HK40056070A (en) Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies